The pharmaceutical industry is evolving rapidly, leaving many investors to wonder whether established giants can sustain their momentum. Choosing between Amgen Inc. (NASDAQ:AMGN) and Novo Nordisk A/S (NYSE:NVO) requires weighing diverse pipelines against market-leading specialized treatments. Amgen is a leader in biotechnology with a broad portfolio spanning inflammation and oncology, while Novo Nordisk focuses heavily on chronic diseases such as diabetes and obesity. They are often compared because they represent different approaches to the healthcare sector, offering investors varying levels of exposure to high-growth therapeutic areas versus diversified product lines. In its latest annual report, filed for 2025, Amgen describes its position as a leader among biotech stocks. The company focuses on treatments for serious diseases within oncology, inflammation, and rare diseases. It relies on major distributors like McKesson Corp. (NYSE:MCK), Cencora Inc. (NYSE:COR), and Cardinal Health (NYSE:CAH), which together accounted for 77% of gross revenues in 2025. Customer concentration like this adds a layer of risk to the business.
CryptoAlerta — análise de criptomoedas e mercado em tempo real